Mesoblast Posts US$115m First-Year Ryoncil Sales and Advances Late-Stage Cell Therapy Pipeline
I'm LongbridgeAI, I can summarize articles.Mesoblast reported US$115 million in first-year Ryoncil sales and advanced its late-stage cell therapy pipeline. The company expanded Ryoncil's label trials to adults and secured FDA clearance for Duchenne muscular dystrophy research. Additionally, it reached patient targets for a chronic low back pain trial and obtained filing numbers for a heart failure therapy. Analyst ratings remain mixed, with some Buy recommendations contrasting against AI-driven Neutral assessments citing weak financials despite strong commercial traction.
An update from Mesoblast ( (MESO) ) is now available.
Mesoblast has reported strong initial commercial traction for its flagship cell therapy Ryoncil®, posting net revenue of US$36 million for the fourth quarter and US$115 million for the first full year following FDA approval, as disclosed in its Appendix 4C activity report for the year ended June 30, 2026. The company ended the period with US$103 million in cash after drawing down US$50 million from a five‑year facility to retire maturing debt, while limiting net operating cash spend to US$43.8 million for the year.
Operationally, Mesoblast is moving to expand Ryoncil’s label beyond children with steroid‑refractory acute graft versus host disease into adults and other severe inflammatory indications, with a registration trial in adult SR‑aGvHD now enrolling at up to 40 U.S. sites and FDA clearance secured for a registrational trial in ambulatory children with Duchenne muscular dystrophy. In parallel, the company has reached its target of treating at least 300 patients in a pivotal Phase 3 trial of rexlemestrocel‑L for chronic low back pain and obtained a Biologics License Application filing number for rexlemestrocel‑L in preventing life‑threatening gastrointestinal bleeding in end‑stage heart failure patients with LVADs, underlining a broader late‑stage pipeline that could materially influence its future revenue profile and positioning in inflammatory and cardiovascular therapeutics.
The most recent analyst rating on (MESO) stock is a Buy
with a $35.00 price target.
To see the full list of analyst forecasts on Mesoblast stock,
see the MESO Stock Forecast page.
Spark’s Take on MESO Stock
According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and cash outflows) and soft technical momentum. These are partially offset by a positive earnings-call outlook, including raised commercial evidence for Ryoncil (strong H1 revenue contribution, 93% gross margin) and clear revenue guidance, while valuation signals are limited due to an unusable P/E and no dividend.
To see Spark’s full report on MESO stock,
click here.
More about Mesoblast
Mesoblast Limited is a global biotechnology company focused on developing allogeneic, off‑the‑shelf cellular medicines for severe and life‑threatening inflammatory conditions. Built on proprietary mesenchymal stromal cell technology platforms, its lead product Ryoncil® is the first FDA‑approved MSC therapy for pediatric steroid‑refractory acute graft versus host disease, with additional programs in heart failure, chronic low back pain and inflammatory bowel disease.
The company commercializes its therapies through partnerships in Japan, Europe and China, supported by a broad intellectual property estate of more than 1,000 granted patents and applications covering cell compositions, manufacturing and indications. Mesoblast operates manufacturing and development sites in Australia, the United States and Singapore and is dual‑listed on the ASX and Nasdaq, positioning it to scale industrial‑grade cell therapies for global markets.
Average Trading Volume: 217,276
Technical Sentiment Signal: Sell
Current Market Cap: $1.86B